Moberg Pharma’s head of U.S. operations to resign by end of January 2015

Moberg Pharma AB (OMX:MOB) today announced that its head of U.S. operations,
Steve Cagle, has announced his resignation. In order to secure a smooth
transition, he will remain in his position until end of January 2015 at the
latest.
"I am proud of the achievements during the last two years. We have almost
doubled the net sales in the U.S. market and made Kerasal Nail® the leading OTC
product for nail fungus related problems", said Steve Cagle.
"Steve and his team have made an excellent job in growing our U.S. business. Our
U.S. sales outpaced the market and grew with 31% in the past 12 months. We have
established a leading position in foot care, added additional brands through
acquisitions and built a strong sales and marketing team. I would like to thank
Steve for his great contribution to Moberg Pharma and wish him success when he
pursues new career opportunities”, said Peter Wolpert, CEO of Moberg Pharma AB.

Steve Cagle has been part of the management team at Moberg Pharma since November
2012. The process to recruit a new head of Moberg’s U.S. subsidiary has been
initiated.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 08.00 am (CET) on August 28th, 2014.
For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se

Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78
Email: peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.